AP865A - Heterecyclic compounds useful as inhibitors of cysteine protease. - Google Patents

Heterecyclic compounds useful as inhibitors of cysteine protease. Download PDF

Info

Publication number
AP865A
AP865A APAP/P/1997/001054A AP9701054A AP865A AP 865 A AP865 A AP 865A AP 9701054 A AP9701054 A AP 9701054A AP 865 A AP865 A AP 865A
Authority
AP
ARIPO
Prior art keywords
scheme
galkyl
compounds
formula
cathepsin
Prior art date
Application number
APAP/P/1997/001054A
Other languages
English (en)
Other versions
AP9701054A0 (en
Inventor
Robert Wells Marquis Jr
Daniel Frank Veber
Yu Ru
Stephen Lo Castro
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AP9701054A0 publication Critical patent/AP9701054A0/xx
Application granted granted Critical
Publication of AP865A publication Critical patent/AP865A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
APAP/P/1997/001054A 1996-08-08 1997-08-06 Heterecyclic compounds useful as inhibitors of cysteine protease. AP865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2374296P 1996-08-08 1996-08-08
US4686797P 1997-05-08 1997-05-08

Publications (2)

Publication Number Publication Date
AP9701054A0 AP9701054A0 (en) 1997-10-31
AP865A true AP865A (en) 2000-08-17

Family

ID=26697548

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001054A AP865A (en) 1996-08-08 1997-08-06 Heterecyclic compounds useful as inhibitors of cysteine protease.

Country Status (35)

Country Link
EP (1) EP0936912B1 (de)
JP (1) JP3948753B2 (de)
KR (1) KR100508045B1 (de)
CN (1) CN1171870C (de)
AP (1) AP865A (de)
AR (1) AR009020A1 (de)
AT (1) ATE259352T1 (de)
AU (1) AU721853B2 (de)
BG (1) BG64412B1 (de)
BR (1) BR9711044A (de)
CA (1) CA2262668C (de)
CY (1) CY2528B1 (de)
CZ (1) CZ297294B6 (de)
DE (1) DE69727586T2 (de)
DK (1) DK0936912T3 (de)
DZ (1) DZ2285A1 (de)
EA (1) EA001937B1 (de)
ES (1) ES2213831T3 (de)
HU (1) HU222788B1 (de)
ID (1) ID18001A (de)
IL (1) IL128378A (de)
MA (1) MA24298A1 (de)
MY (1) MY116947A (de)
NO (1) NO317182B1 (de)
NZ (1) NZ333987A (de)
OA (1) OA10972A (de)
PE (1) PE99198A1 (de)
PL (1) PL191779B1 (de)
PT (1) PT936912E (de)
RO (1) RO120407B1 (de)
SK (1) SK285127B6 (de)
TR (1) TR199900249T2 (de)
TW (1) TW542825B (de)
UY (2) UY24660A1 (de)
WO (1) WO1998005336A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK56798A3 (en) 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
US6566373B2 (en) * 1997-05-06 2003-05-20 Smithkline Beecham Corporation Protease inhibitors
TR199902752T2 (xx) * 1997-05-08 2000-06-21 Smithkline Beecham Corporation Proteaz inhibit�rleri.
CN1158269C (zh) 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
MA26618A1 (fr) * 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
AU2003261482B2 (en) * 1998-12-23 2007-01-25 Smithkline Beecham Corporation Protease inhibitors
CO5180541A1 (es) * 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
EP1384713B1 (de) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
BR9916488A (pt) * 1998-12-23 2001-10-09 Smithkline Beecham Corp Inibidores de protease
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
WO2001034600A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034157A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034154A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034153A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513923A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
AU1588901A (en) * 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
JP2003513924A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
AU1474701A (en) * 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
JP2003513928A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
EP1235577A4 (de) * 1999-11-10 2003-04-09 Smithkline Beecham Corp Proteaseinhibitoren
OA12323A (en) 2000-03-21 2006-05-15 Smithkline Beecham Corp Protease inhibitors.
CO5280088A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
HUP0301231A2 (hu) * 2000-06-14 2003-08-28 Smithkline Beecham Corp. Proteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2002017924A1 (en) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Method of treatment
HUP0303360A2 (hu) * 2000-09-25 2004-01-28 Actelion Pharmaceuticals Ltd. Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
PT1362052E (pt) 2001-01-17 2007-04-30 Amura Therapeutics Ltd Inibidores de cruzipaína e de outras proteases de cisteína
CA2434068A1 (en) 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
MXPA03007621A (es) 2001-02-23 2003-12-04 Merck & Co Inc Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos.
US6710061B2 (en) 2001-03-09 2004-03-23 Ortho-Mcneil Pharamceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US6538017B2 (en) 2001-03-09 2003-03-25 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
EP1390034A4 (de) 2001-04-03 2005-07-13 Merck & Co Inc N-substituierte nonaryl-heterocyclo amidyl-nmda/nr2b-antagonisten
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
EP1446392A1 (de) 2001-11-14 2004-08-18 Aventis Pharmaceuticals, Inc. Oligopeptide und diese enthaltende zusammensetzungen als cathepsininhibitoren
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
RU2312861C2 (ru) * 2002-03-05 2007-12-20 Мерк Фросст Кэнада Лтд. Ингибиторы катепсин-цистеинпротеазы
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
CN100368018C (zh) * 2005-05-26 2008-02-13 福建医科大学 蛇毒半胱氨酸蛋白酶抑制剂抗肿瘤侵袭与转移作用及应用
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994471A (en) * 1989-05-12 1991-02-19 Boc, Inc. N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
US5216168A (en) * 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5206251A (en) * 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
US5585387A (en) * 1994-10-07 1996-12-17 Torcan Chemical Ltd. Prepration of cisapride
SK56798A3 (en) * 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4994471A (en) * 1989-05-12 1991-02-19 Boc, Inc. N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
US5216168A (en) * 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars

Also Published As

Publication number Publication date
RO120407B1 (ro) 2006-01-30
CN1232399A (zh) 1999-10-20
MA24298A1 (fr) 1998-04-01
MY116947A (en) 2004-04-30
TW542825B (en) 2003-07-21
WO1998005336A1 (en) 1998-02-12
EP0936912A1 (de) 1999-08-25
HK1022096A1 (en) 2000-07-28
NO990548D0 (no) 1999-02-05
SK16299A3 (en) 1999-12-10
EP0936912A4 (de) 1999-10-13
HUP9902409A2 (hu) 1999-11-29
EA199900186A1 (ru) 2000-04-24
ES2213831T3 (es) 2004-09-01
UY24660A1 (es) 1998-02-03
CA2262668A1 (en) 1998-02-12
DZ2285A1 (fr) 2002-12-25
ATE259352T1 (de) 2004-02-15
SK285127B6 (sk) 2006-06-01
OA10972A (en) 2003-03-04
NZ333987A (en) 2000-09-29
AR009020A1 (es) 2000-03-08
JP2000516920A (ja) 2000-12-19
CY2528B1 (en) 2006-04-12
AP9701054A0 (en) 1997-10-31
CA2262668C (en) 2006-05-09
DE69727586D1 (en) 2004-03-18
IL128378A0 (en) 2000-01-31
CN1171870C (zh) 2004-10-20
BR9711044A (pt) 2000-10-24
JP3948753B2 (ja) 2007-07-25
KR20000029863A (ko) 2000-05-25
PE99198A1 (es) 1999-03-07
IL128378A (en) 2003-10-31
AU721853B2 (en) 2000-07-13
UY24863A1 (es) 2001-07-31
DK0936912T3 (da) 2004-06-07
KR100508045B1 (ko) 2005-08-17
PL191779B1 (pl) 2006-07-31
EA001937B1 (ru) 2001-10-22
BG64412B1 (bg) 2005-01-31
AU3972697A (en) 1998-02-25
CZ297294B6 (cs) 2006-11-15
ID18001A (id) 1998-02-19
PL331533A1 (en) 1999-07-19
HU222788B1 (hu) 2003-10-28
DE69727586T2 (de) 2004-12-16
TR199900249T2 (xx) 1999-04-21
PT936912E (pt) 2004-06-30
EP0936912B1 (de) 2004-02-11
BG103144A (en) 1999-09-30
NO990548L (no) 1999-04-07
CZ36299A3 (cs) 1999-07-14
NO317182B1 (no) 2004-09-06
HUP9902409A3 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
ES2259617T3 (es) Compuestos heterociclicos y su aplicacion como medicamentos.
CA2262668C (en) Inhibitors of cathepsin k
EP0277588B1 (de) Prolinalderivate
KR950013849B1 (ko) 프롤리날 유도체 이의 제조방법 및 이를 포함하는 약제학적 조성물
FR2609716A1 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments
NZ337889A (en) Cysteine Protease inhibitors of the Papain superfamily comprising cathepsin K protease inhibitors
WO1998008802A1 (en) Inhibitors of cysteine protease
CZ144798A3 (cs) Nové makrocyklické sloučeniny jako metaloproteinázové inhibitory
JP2001501193A (ja) システイン・プロテイナーゼ調節剤としての４―置換―３―（２―アミノ―２―シクロアルキルメチル）―アセトアミドアゼチジン―２―オン誘導体
EP0280956A1 (de) Thiazolidin-Derivate
CA2332492A1 (en) Protease inhibitors
CA2334652A1 (en) Protease inhibitors
WO2000058296A1 (en) Protease inhibitors
US6566373B2 (en) Protease inhibitors
EP1384713B1 (de) 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
WO2001040263A1 (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
CA2348048A1 (en) Method of producing peptidylaldehyde
EP0900566A1 (de) Neuartige tripeptidvebindungen und arzneimittel gegen aids
Clive et al. Synthesis and in vitro activity of a non-epimerizable analog of the angiotensin-converting enzyme inhibitor A58365A
US20020082426A1 (en) Protease inhibitors
JPH05163221A (ja) オキシ酸誘導体
MXPA99010254A (en) Protease inhibitors
JPWO2000024704A1 (ja) ペプチジルアルデヒドの製造法
EP1503991A1 (de) Hexahydropyridazin-3-carbonsäurederivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung